| capecitabine / Generic mfg. |
POLESTAR, NCT05268510: Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib as Firstline Therapy in Her-2 Negative Gastric/GEJ Adenocarcinoma |
|
|
| Active, not recruiting | 2a | 31 | Europe | Pembrolizumab, Keytruda, Olaparib, Lynparza, mFOLFOX-6, CapOX | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Esophagogastric Adenocarcinoma | 09/26 | 03/27 | | |
ACTRN12610000440022: CLEMENT Capecitabine-radiosensitizing Lutetium-177 octreotate endoradiotherapy management of endocrine neurogenic tumours
Response and Toxicity Assessment |
|
|
| Recruiting | 2 | 75 | | | Fremantle Hospital Health Service, Government of WA Cancer Network | Neuroendocrine tumour, Neuroendocrine malignancy | | | | |
jRCTs031220572: Phase II study of CapeOX + nivolumab therapy for early recurrent gastric cancer |
|
|
| Recruiting | 2 | 92 | Japan | capecitabine - Generic mfg., Opdivo (nivolumab) - Ono Pharma, BMS, oxaliplatin - Generic mfg. | St. Marianna University Hospital, ONO PHARMACEUTICALO CO., LTD., Bristol-Myers Squibb Company | Early relapsed gastric cancer | | | | |
ACTRN12616001536459: Oxaliplatin Dose Modification for Colorectal Cancer Triggered by Patient Reported Toxicity: Acceptability and Effect on Chronic Chemotherapy Induced Peripheral Neuropathy |
|
|
| Recruiting | 2 | 30 | | | MidCentral Regional Cancer Treatment Services, MidCentral Regional Cancer Treatment Services | metastatic colorectal cancer, chemotherapy induced peripheral neuropathy | | | | |
ACTRN12618001480279: Comparing alternating oxaliplatin and irinotecan chemotherapy versus standard of care for metastatic colorectal cancer. |
|
|
| Recruiting | 2 | 140 | | | The Walter and Eliza Hall Institute of Medical Research, Victorian Comprehensive Cancer Centre | Metastatic Colorectal Cancer | | | | |
ACTRN12619000409178: A Randomised Phase II Study of MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease (MASTERPLAN) |
|
|
| Recruiting | 2 | 120 | | | Australasian Gastro-Intestinal Trials Groups (AGITG), Australian Government Department of Health, Medical Research Future Fund (MRFF) | PANCREATIC CANCER | | | | |
ACTRN12619001117101: BCT 1901 (CAPTURE): Women or men with oestrogen receptor positive, HER2 negative advanced breast cancer and PIK3CA mutant circulating DNA will be randomised to evaluate treatment with alpelisib plus fulvestrant compared with capecitabine on progression free survival. |
|
|
| Recruiting | 2 | 66 | | | Breast Cancer Trials, National Health and Medical Research Council | Advanced Breast Cancer | | | | |
ENSEMBLE-2, jRCTs071210143: A multi center, phase 2 study to Evaluate safety and efficacy of total Neoadjuvant treatment of long courSE radiotherapy followed by cheMotherapy, capecitaBine combined with oxaliplatin (CAPOX) for Locally advanced rEctal cancer |
|
|
| Active, not recruiting | 2 | 27 | Japan | capecitabine - Generic mfg., oxaliplatin - Generic mfg. | Osaka General Medical Center | Rectal cancer | | | | |
RC48-C022, CTR20233553: A phase II clinical study to evaluate the efficacy and safety of injectable vedicitumab plus toripalimab with or without chemotherapy (capecitabine + oxaliplatin) versus chemotherapy for the perioperative treatment of resectable locally advanced gastric/g |
|
|
| Recruiting | 2 | 90 | China | Aidixi (disitamab vedotin) - Rongchang Pharma, Pfizer, Loqtorzi (toripalimab) - Shanghai Junshi Biosci, Coherus Biosci, capecitabine - Generic mfg., oxaliplatin - Generic mfg. | Remegen Biopharmaceutical (Yantai) Co., Ltd | HER2-expressing resectable locally advanced gastric/gastroesophageal junction adenocarcinoma | | | | |
ChiCTR-TRC-11001439: Establishment of subcutaneous transplantation tumor model and application in adjuvant chemotherapy of gastric cancer |
|
|
| Completed | 2 | 100 | | chemotherapy by the outcome of chemosensitivity assay ;chemotherapy (EOF, DC, XELOX, S-1) | Nantong Tumor Hospital; Shanghai ChemPartner Co., LTD, Shanghai ChemPartner Co., LTD | gastric cancer | | | | |
NCT00806949: Epirubicin, Oxaliplatin, and Capecitabine or Docetaxel and Oxaliplatin in Treating Patients With Advanced Esophageal Cancer, Gastroesophageal Junction Cancer, or Stomach Cancer |
|
|
| Recruiting | 2 | 140 | Europe | capecitabine, docetaxel, epirubicin hydrochloride, oxaliplatin | All Ireland Cooperative Oncology Research Group | Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer | 12/09 | | | |
ChiCTR-TNC-09000349: A phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer. |
|
|
| Completed | 2 | 20 | | pemetrexed | Zhejiang Cancer Hospital; Eli Lilly and Company, 1. Zhejiang Cancer Hospital; 2. Eli Lilly and Company | advanced breast cancer | | | | |
2010-022065-10: Effect of angiogenesis inhibiting therapy in patients progressing on endocrine treatment and patients with triple negative breast cancer - a translational phase II study within the Swedish Association of Breast Oncologists SABO-2010-01 |
|
|
| Ongoing | 2 | 40 | Europe | Concentrate for solution for infusion, Film-coated tablet, Avastin, Xeloda, Sendoxan | Sahlgrenska University Hospital | Patients with breast cancer who are oestrogen receptor positive but HER2 negative and progressing on endocrine therapy. Patients with locally advanced or recurrent triple negative breast cancer (TNBC) can also be included. Patients with TNBC will not receive endocrine therapy., Patients with breast cancer who are oestrogen receptor positive but HER2 negative and progressing on endocrine therapy. Patients with locally advanced or recurrent triple negative breast cancer (TNBC), Diseases [C] - Cancer [C04] | | | | |
2009-017083-16: A phase II study of metronomic oral chemoterapy with Cyclophosphamide plus Capecitabine combined with Trastuzumab in advanced breast cancer |
|
|
| Ongoing | 2 | 66 | Europe | Powder for infusion*, Film-coated tablet, HERCEPTIN, XELODA, ENDOXAN BAXTER | GOIM GRUPPO ONCOLOGICO MERIDIONALE | Pre-or post-menopausal women with histologically proven, locally advanced (inoperable) or metastatic breast cancer. | | | | |
2011-001720-37: Multi-centre, phase II, single arm study of the docetaxel, oxaliplatin, capecitabine (DOC) combination in untreated patients with advanced or metastatic gastric cancer Studio di fase II della combinazione di docetaxel, oxaliplatino e capecitabina (DOC) in pazienti affetti da carcinoma gastrico non pre-trattati |
|
|
| Ongoing | 2 | 71 | Europe | Concentrate for solution for infusion, Tablet, TAXOTERE*INFUS FL 160MG/8ML, OXALIPLATINO TEVA*INF 100MG/20, XELODA*120CPR RIV 500MG | CENTRO DI RIFERIMENTO ONCOLOGICO DI AVIANO, Centro di Riferimento Oncologico IRCCS CRO Aviano | patients with metastatic gastric carcinoma pazienti affetti da carcinoma gastrico metastatico, patients with metastatic gastric carcinoma pazienti affetti da carcinoma gastrico metastatico, Diseases [C] - Cancer [C04] | | | | |
2012-000393-35: a multicenter phase II trial of nab-paclitaxel and capecitabine as first line treatment in Her-2 neg. metastatic breast cancer studio di fase II, in pazienti affette da carcinoma della mammella metastatico Her-2 neg. e triple neg., I linea, utilizzando ABX e capecitabina |
|
|
| Ongoing | 2 | 94 | Europe | abraxane, xeloda, NA, Solution for infusion, Capsule, hard | GOIM GRUPPO ONCOLOGICO MERIDIONALE, studio no profit | metastatic breast cancer (MBC) Her-2 negative as first line treatment carcinoma della mammella metastatico Her-2 neg e triple neg. in trattamento di I linea, metastatic breat cancer Her-2, pgr, Er negative carcinoma della mammella con metastasi con her2, Pgr, Er negativi, Diseases [C] - Cancer [C04] | | | | |
2012-002053-29: PET/CT-biopsi study A PET/CT biopsy study in patients Capecitabine +/- Sorafenib in the treatment of locally advanced or metastatic HER2-negative breast cancer. "PET/CT-biopsi studie" på patienter med Capecitabine +/- Sorafenib vid behandling av avancerad bröstcancer |
|
|
| Ongoing | 2 | 20 | Europe | Nexavar, Xeloda - 150 mg, Xeloda - 500 mg, -, Film-coated tablet, Nexavar, Xeloda | Karolinska Institutet and University Hospital, Karolinska Institutet and University Hospital | Morphological verifications of metastatic lesions, PET Ribonucleic Acid (RNA)-expression study in subjects with locally advance or metastatic HER2-negative breast cancer., PET/CT trial in subjects who are participating in trial 12444 with EudraCT number 2010-018501-10, Diseases [C] - Cancer [C04] | | | | |
NCT01330212: PET-Guided Chemotherapy and Hormone Therapy in Treating Women With Previously Untreated Invasive Breast Cancer |
|
|
| Recruiting | 2 | 60 | US | bevacizumab, trastuzumab, capecitabine, cyclophosphamide, docetaxel, epirubicin hydrochloride, vinorelbine tartrate, gene expression analysis, microarray analysis, neoadjuvant therapy, positron emission tomography, therapeutic conventional surgery | Auxilio Mutuo Cancer Center | Breast Cancer | 03/13 | | | |
2013-001203-36: Clinical trial to assess wether Lapatinib in association with Capecitabine and Radiation performs better than Capecitabine and Radiation in patients with localized rectal cancer Ensaio clínico para avaliar se a associação de Lapatinib com Capecitabina e Radioterapia é melhor do que Capecitabina e Radioterapia em doentes com cancro do recto localizado |
|
|
| Ongoing | 2 | 80 | Europe | Film-coated tablet, Tyverb | Instituto Português de Oncologia do Porto Francisco Gentil, EPE, GlaxoSmithKline, IPO Porto FG, EPE | Rectal cancer stage II Rectal cancer stage III Cancro do Reto, estádio II Cancro do Reto, estádio III, Rectal Cancer Cancro do Reto, Diseases [C] - Cancer [C04] | | | | |
2013-001096-20: Salvage chemotherapy with daily, low, continuously administered dose of capecitabine and proton-pump inhibitors in advanced gastro-intestinaltumours Terapia di salvataggio con basse dosi di Capecitabina, giornaliera, continuativa, associata ad inibitori di pompa protonica nei tumorigastrointestinali avanzati |
|
|
| Ongoing | 2 | 66 | Europe | Pariet, Xeloda, Capsule, hard, Pariet, Xeloda | Department of Molecular and Clinical Medicine; "Sapienza" University of Rome, Department of Molecular and Clinical Medicine; "Sapienza" University of Rome | Patients with gastrointestinal malignancies ineligible for conventional chemotherapy Pazienti con neoplasie gastrointestinali non eleggibili per un trattamento chemioterapico convenzionale, Patients with advanced tumors of the gastrointestinal tract Pazienti con tumori del tratto gastroenterico avanzati, Diseases [C] - Cancer [C04] | | | | |
2013-001483-39: XELODA metronomic IN PATIENTS WITH advanced hepatocellular carcinoma AND FUNCTIONALITY 'LIVER CHILD-PUGH B XELODA METRONOMICO NEI PAZIENTI CON EPATOCARCINOMA AVANZATO e FUNZIONALITA' EPATICA CHILD-PUGH B |
|
|
| Ongoing | 2 | 43 | Europe | XELODA | Istituto Oncologico Veneto, Istituto Oncologico Veneto | PATIENTS WITH advanced hepatocellular carcinoma AND FUNCTIONALITY 'LIVER CHILD-PUGH B PAZIENTI CON EPATOCARCINOMA AVANZATO e FUNZIONALITA' EPATICA CHILD-PUGH B, PATIENTS WITH ADVANCED LIVER CANCER AND HEPATIC FUNCTIONALITY CHILD-PUGH B PAZIENTI CON TUMORE DEL FEGATO AVANZATO e FUNZIONALITA' EPATICA CHILD-PUGH B, Diseases [C] - Cancer [C04] | | | | |
ChiCTR-TNC-10001094: Preoperative Concurrent Boosting Intensity-Modulated Radiotherapy with Oral Capecitabine in Locally Advanced Mid-Low Rectal Cancer |
|
|
| Recruiting | 2 | 63 | | Preoperative IMRT (GTV 50.6Gy/22 fractions, CTV 41.8 Gy/22 frations, the boost to the primary tumor would be administered synchronously with the whole pelvis) with concurrent capecitabine 825 mg/m2 twice daily 5 days per week. | Beijing Cancer Hospital; Level of the institution：, Beijing Cancer Hospital | Rectal cancer | | | | |
ChiCTR-ONC-13003949: Irinotecan and capecitabine with concurrent chemoradiotherapy for unresectable advanced gastric carcinoma |
|
|
| Completed | 2 | 60 | | Irinotecan and capecitabine with concurrent chemoradiotherapy | Cancer Center of Union Hospital, Wuhan; Cancer Center of Union Hospital, Wuhan, Cancer Center of Union Hospital, Wuhan | Unresectable advanced gastric carcinoma | | | | |
ChiCTR-OIC-17011632: Phase II study of preoperative radiotherapy with capecitabine and oxaliplatin for rectal cancer |
|
|
| Completed | 2 | 47 | | pre-operative radiotherapy with concurrent capecitabine and oxaliplatin | Sun Yat-sen University Cancer Center; None, None | Rectal cancer | | | | |
| Active, not recruiting | 2 | | Europe | Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Trastuzumab | The Netherlands Cancer Institute | Metastatic Gastric Cancer, Adenocarcinoma of the Gastro-oesophageal Junction | 05/15 | | | |
ECRP, ChiCTR-ONC-13003720: Clinical study of Endostar plus capecitabine combined with stereotactic radiotherapy in the treatment of advanced pancreatic cancer subjects open, single group phase II |
|
|
| Completed | 2 | 100 | | Recombinant Human Endostatin Injection ;Capecitabine Tablet | Daping Hospital, Third Military Medical University; None, self-collected funds | Advanced pancreatic cancer | | | | |
2010-022793-14: A prospective, multicentre, open-label, randomised, uncontrolled, phase 1/2 study to evaluate the efficacy and safety of masitinib in combination with 5-fluorouracil (5-FU) or capecitabine, or masitinib in combination with irinotecan, or masitinib in combination with irinotecan, 5-fluorouracil (5-FU) and folinic acid (FOLFIRI protocol), as second line chemotherapy in patients with gastric or gastro-oesophageal junction metastatic adenocarcinoma. |
|
|
| Not yet recruiting | 2 | 57 | Europe | masitinib, Irinotecan, AB1010, Film-coated tablet, Solution for infusion, Irinotecan/Campto®/Camptosar® | AB Science | gastric or gastro-oesophageal junction metastatic adenocarcinoma | | | | |
2006-003752-38: A phase II study of Capecitabine in combination with oral vinorelbine in advanced Breast Cancer |
|
|
| Ongoing | 2 | 43 | Europe | XELODA*120CPR RIV 500MG, NAVELBINE*1CPS 30MG, XELODA*60CPR RIV 150MG, XELODA*120CPR RIV 500MG, NAVELBINE*1CPS 30MG, XELODA*60CPR RIV 150MG | OSPEDALE ONCOLOGICO DI BARI | advancer breast carcinoma | | | | |
2004-000665-35: Study to assess the efficacy and safety of oral vinorelbine in combination with capecitabine in patients suffering from breast cancer previously treated with other chemotherapies (anthracyclines, and taxanes) Estudio para evaluar la eficacia y seguridad de vinorelbina oral en combinación con capecitabina en pacientes con cáncer de mama previamente tratadas on otras quimioterapias (antraciclinas y taxanos) |
|
|
| Ongoing | 2 | 15 | Europe | Navelbine Cápsulas Blandas, Xeloda, Not applicable, Navelbine Capsulas blandas, Xeloda, Navelbine Capsulas blandas, Xeloda | Pierre Fabre Medicament, Pierre Fabre Medicament | Treatment in metastatic breast cancer women previously treated with anthracyclines and taxanes | | | | |
2004-001159-12: A randomized phase II study of oxaliplatin and capecitabine combination vs irinotecan and capecitabine combination for the treatment of elderly patients with advanced colorectal cancer. |
|
|
| Ongoing | 2 | 94 | Europe | ELOXATIN*IV 1FL POLV 100MG, XELODA*120CPR RIV 500MG, CAMPTO*1FL 100MG/5ML, ELOXATIN*IV 1FL POLV 100MG, XELODA*120CPR RIV 500MG, CAMPTO*1FL 100MG/5ML | AZIENDA OSPEDALIERA S. CARLO | elderly patients affected by advanced colorectal cancer | | | | |
2004-000748-26: Phase II trial of oral vinorelbine in combination with capecitabine and trastuzumab as first line therapy in women with previously untreated HER2 positive metastatic breast cancer. |
|
|
| Ongoing | 2 | 12 | Europe | Navelbine Cápsulas Blandas, Xeloda, Herceptin 150 mg, Not applicable, Navelbine Cápsulas Blandas, Xeloda 500 mg 120 commprimidos cubierta pelicular, Herceptin 150 mg, Navelbine Cápsulas Blandas, Xeloda 500 mg 120 commprimidos cubierta pelicular, Herceptin 150 mg | Pierre Fabre Ibérica, S.A. en representación de Pierre Fabre Mèdicament | Treatment in women with previously untreated HER2 positive metastatic breast cancer. | | | | |
2004-000753-30: Phase II trial of oral vinorelbine in combination with capecitabine as first line therapy in women with previously untreated HER2 negative metastatic breast cancer. |
|
|
| Ongoing | 2 | 15 | Europe | Navelbine Soft Capsules, Xeloda, Not applicable, NA, Navelbine Cápsulas Blandas, Xeloda 500 mg 120 comprimidos cubierta pelicular, Navelbine Cápsulas Blandas, Xeloda 500 mg 120 comprimidos cubierta pelicular | Pierre Fabre Ibérica S.A. as legal representative of Pierr Fabre Mèdicament | Treatment in women with previously untreated HER2 negative metastatic breast cancer. | | | | |
2004-002376-42: PHASE II TRIAL OF SEQUENTIAL CHEMO-IMMUNOTHERAPY WITH CAPECITABINE PLUS INTERFERON ALPHA2a FOLLOWED BY IL-2 IN PATIENTS WITH METASTATIC KIDNEY CANCER |
|
|
| Ongoing | 2 | 36 | Europe | XELODA 120 CPR RIV. 500MG, XELODA 120 CPR RIV. 500MG | G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST | TREATMENT OF METASTATIC KIDNEY CANCER | | | | |
2004-001926-26: XERXES: Examining the role of early neoadjuvant and synchronous Erbitux in pre-operative chemo-radiotherapy using Xeloda followed by excisional surgery. A phase I/II dose escalation study of intravenous erbitux (cetuximab) in combination with 5 day weekly oral Xeloda (capecitabine) and preoperative radiotherapy in rectal cancer. |
|
|
| Ongoing | 2 | 48 | Europe | Erbitux, Xeloda, n/a, Erbitux, Erbitux | University College London | Locally advanced rectal cancer | | | | |
2005-002181-11: FOLFIRI vs XELIRI in the treatment of advanced colo-rectal untreated carcinoma: a phase II randomized study of the Gruppo Oncologico dell\'Italia Meridionale |
|
|
| Ongoing | 2 | 111 | Europe | CAMPTO*1FL 100MG/5ML, LEDERFOLIN*INFUS 1FL 100MG, FLUOROURACILE TEVA*IV FL 5G, XELODA*120CPR RIV 500MG, CAMPTO*1FL 100MG/5ML, LEDERFOLIN*INFUS 1FL 100MG, FLUOROURACILE TEVA*IV FL 5G, XELODA*120CPR RIV 500MG | OSPEDALE ONCOLOGICO DI BARI | Untreated colo-rectal carcinoma | | | | |
2005-001271-35: ASSOCIATION OF CAPECITABINA And GEMCITABIN In METASTATIC MAMMARY CARCINOMA CLINICAL STUDY of Dose-finding and Activity Of the ASSOCIATION PHASE I-II |
|
|
| Ongoing | 2 | 40 | Europe | XELODA 120 CPR RIV. 500MG, GEMZAR 1G POLV. EV 1 FL, GEMZAR 200MG POLV. EV 1FL, XELODA 120 CPR RIV. 500MG, GEMZAR 1G POLV. EV 1 FL, GEMZAR 200MG POLV. EV 1FL | AZIENDA USL 6 LIVORNO ZONA LIVORNESE | Capecitabina and gemcitabina are singularly active drugs in the dealt breast cancer and with various profile of toxicity;they exist give to you preclinical of synergy in vitro between two drugs;they do not exist give to you defined you approximately the dose in association to use | | | | |
2005-003676-38: CAPECITABINE TIME TABLE AND RADIOTHERAPY AS ADJUVANT THERAPY IN RECTAL CANCER |
|
|
| Ongoing | 2 | 38 | Europe | XELODA 120CPR RIV 500MG, XELODA 120CPR RIV 500MG | ISTITUTO NAZIONALE PER LA CURA TUMORI | This trial evaluates safety diarrhea, proctitis and cistitis of Grade 3/4 of radiochemotherapy with time table Capecitabine as adjuvant treatment in rectal cancer after radical surgery. | | | | |
2005-005683-87: VINORELBINA CAPECITABIME PACLITAXEL AS FIRST LINE THERAPY IN ADVANCED BREAST CANCER PATIENTS PRETREATED WITH ADJUVANT ANTHRACYCLINES |
|
|
| Ongoing | 2 | 66 | Europe | NAVELBINE 10MG/ML FL1ML, XELODA 120 CPR RIV. 500MG, TAXOL 30MG/5 ML IV 1FL, NAVELBINE 10MG/ML FL1ML, XELODA 120 CPR RIV. 500MG, TAXOL 30MG/5 ML IV 1FL | AZIENDA OSPEDALIERA S. LUIGI GONZAGA | METASTATIC BREAST CANCER | | | | |
2005-005681-36: VINORELBINE CAPECITABINE EPIRUBICINE AS FIRST LINE THERAPY IN ADVANCED BREAST CANCER PATIENTS |
|
|
| Ongoing | 2 | 66 | Europe | NAVELBINE 10MG/ML FL1ML, XELODA 120 CPR RIV. 500MG, FARMORUBICINA 10MG/5ML IV1FL, NAVELBINE 10MG/ML FL1ML, XELODA 120 CPR RIV. 500MG, FARMORUBICINA 10MG/5ML IV1FL | AZIENDA OSPEDALIERA S. LUIGI GONZAGA | METASTATIC BREAST CANCER | | | | |
2005-005680-29: VINORELBINE AND CAPECITABINE as first line treatment in advanced breast cancer patients with non measurable lesions for RECIST criteria |
|
|
| Ongoing | 2 | 100 | Europe | vinorelbina, capecitabina, Navelbine 10IV 10mg 1ml, Xeloda 120cpr riv 500mg, Navelbine 10IV 10mg 1ml, Xeloda 120cpr riv 500mg | AZIENDA OSPEDALIERA S. LUIGI GONZAGA | metastatic breast cancer | | | | |
2005-005661-11: PHASE II STUDY OF NEOADJUVANT CHEMORADIOTHERAPY IN LOCALLY ADVANCED RECTAL CANCER |
|
|
| Ongoing | 2 | 43 | Europe | XELODA*120CPR RIV 500MG, ELOXATIN*IV 1FL POLV 100MG, XELODA*120CPR RIV 500MG, ELOXATIN*IV 1FL POLV 100MG | AZIENDA SANITARIA OSPEDALIERA \"S. GIOVANNI BATTISTA DI TORINO\" | rectal cancer | | | | |
2009-015658-39: A PILOT STUDY TESTING THE FEASIBILITY OF TWO DIFFERENTS REGIMENS INCORPORATING DOSE-DENSE DOCETAXEL AND CAPECITABINE-ORAL VINORELBINE IN THE ADJUVANT TREATMENT OF EARLY BREAST CANCER PATIENTS |
|
|
| Ongoing | 2 | 30 | Europe | Concentrate for solution for infusion, Concentrate for solution for injection, Powder and solvent for solution for infusion, Film-coated tablet, Capsule, soft | AZIENDA USL 4 PRATO | BREAST CANCER | | | | |
2006-000834-11: Estudio multicéntrico fase II, abierto, de tratamiento con cetuximab y capecitabina en primera línea de tratamiento en pacientes ancianos con un cáncer colorrectal metastático |
|
|
| Ongoing | 2 | 45 | Europe | Erbitux, Xeloda, EMD271786, Erbitux, Xeloda, Erbitux, Xeloda | Grupo de Tratamiento de los Tumores Digestivos (TTD) | Cáncer colorrectal metastásico | | | | |
2006-002992-42: A phase II study to evaluate the efficacy of bevacizumab in combination with capecitabine and concomitant radiotherapy in patients affected by non-resectable locally advanced pancreatic cancer. |
|
|
| Ongoing | 2 | 65 | Europe | AVASTIN*INFUS 1FL 100MG, XELODA*120CPR RIV 500MG, AVASTIN*INFUS 1FL 100MG, XELODA*120CPR RIV 500MG | AZIENDA SANITARIA OSPEDALIERA \"S. GIOVANNI BATTISTA DI TORINO\" | Locally advanced pancreatic cancer. | | | | |
2005-005846-37: STUDY MULTICENTRIC PILOT OF CHEMOTHERAPY WITH CAPECITABINE, OXALIPLATIN LOHP IRINOTECAN Cpt-11 IN PATIENTS WITH Colorectal METASTATIC cancer |
|
|
| Ongoing | 2 | 45 | Europe | XELODA 120 CPR RIV. 500MG, CAMPTO 1 FL 100 MG/5ML, CAMPTO 1 FL 40 MG/2ML, ELOXATIN IV 1 FL 100 MG, ELOXATIN IV 1 FL 50 MG, XELODA 120 CPR RIV. 500MG, CAMPTO 1 FL 100 MG/5ML, CAMPTO 1 FL 40 MG/2ML, ELOXATIN IV 1 FL 100 MG, ELOXATIN IV 1 FL 50 MG | G.O.N.O. Gruppo Oncologico del Nord Ovest | Patients with metastatic colon-rectal cancer | | | | |
2006-004052-20: Phase II study of definitive radiochemotherapy for locally advanced squamous cell cancer of the vulva: an efficacy study |
|
|
| Ongoing | 2 | 68 | Europe | Xeloda, Xeloda | Koningin Wilhelmina Fonds | advanced stage squamous cell cancer of the vulva | | | | |
2006-003929-83: Phase II study of Bevacizumab in combination with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer. |
|
|
| Ongoing | 2 | 80 | Europe | XELODA*60CPR RIV 150MG, TAXOTERE*INFUS FL 20MG/0,5ML+F, AVASTIN*INFUS 1FL 100MG, XELODA*60CPR RIV 150MG, TAXOTERE*INFUS FL 20MG/0,5ML+F, AVASTIN*INFUS 1FL 100MG | GRUPPO ONCOLOGICO ITALIANO DI RICERCA | Patients with advanced breast cancer | | | | |
2006-006058-83: Phase II randomized trial of combination therapy of paclitaxel and bevacizumab versus paclitaxel, capecitabine and bevacizumab as first-line treatment for locally recurrent or metastatic breast cancer patients with HER2/neu negative tumor (ATX-study) |
|
|
| Ongoing | 2 | 312 | Europe | Avastin, Xeloda, paclitaxel, paclitaxel, Avastin, Xeloda, Taxol, Avastin, Xeloda, Taxol | VU Medisch Centrum | locally recurrent or metastatic breast cancer | | | | |
2007-000725-22: “Estudio abierto, para evaluar el tratamiento con taxotere, cisplatino y capecitabina (TCX) en pacientes con Cáncer Gástrico Avanzado” |
|
|
| Ongoing | 2 | 65 | Europe | CISPLATINO, TAXOTERE 20 MG, TAXOTERE 80 MG, XELODA 150 MG, XELODA 500 MG, TAXOTERE 20 MG, TAXOTERE 80 MG, XELODA 150 MG, XELODA 500 MG | ACROSS (Associació catalana per la recerca oncològica i les seves implicacions sanitàries i socials) | CANCER GASTRICO AVANZADO | | | | |
2006-002152-16: Phase II randomized study of intravenous bevacizumab with sequential versus concurrent oral vinorelbine plus capecitabine in patients with locally advanced or recurrent breast cancer with lymphangitic spread to the chest wall. |
|
|
| Ongoing | 2 | 46 | Europe | AVASTIN*INFUS 1FL 400MG, NAVELBINE*1CPS 30MG, XELODA*120CPR RIV 500MG, NAVELBINE*1CPS 20MG, AVASTIN*INFUS 1FL 100MG, XELODA*60CPR RIV 150MG, AVASTIN*INFUS 1FL 400MG, NAVELBINE*1CPS 30MG, XELODA*120CPR RIV 500MG, NAVELBINE*1CPS 20MG, AVASTIN*INFUS 1FL 100MG, XELODA*60CPR RIV 150MG | ISTITUTO EUROPEO DI ONCOLOGIA | locally advanced or recurrent breast cancer with lymphangitic spread to the chest wall. | | | | |
2007-002682-12: Protocol GI-04A PHASE II TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF BEVACIZUMAB IN COMBINATION WITH CAPECITABINE (XELODA) IN FRAIL PATIENTS WITH UNTREATED METASTATIC COLORECTAL CANCER |
|
|
| Ongoing | 2 | 50 | Europe | Bevacizumab, Xeloda, RO4876646, Avastin, Capecitabine, Avastin, Capecitabine | ICORG | FRAIL PATIENTS WITH UNTREATED METASTATIC COLORECTAL CANCER | | | | |
2007-003221-25: XINACT: To evaluate the benefit of specific drug combinations in reducing cancer tissue in the breast in women who have large breast cancers but confined to the breast and draining lymph glands. |
|
|
| Ongoing | 2 | 120 | Europe | Xeloda, Docetaxel Ebewe, Granocyte, Xeloda, Docetaxel Ebewe, Granocyte | United Lincolnshire Hospitals NHS Trust, , Roche Pharma UK; Sanofi Aventis Pharma UK; Chugai Pharma UK, | Large (>/=3 cm) or locally advanced breast cancers | | | | |
2008-000934-35: Activities of prolonged administration of vinorelbine or capecitabine oral to increase time to progression in patients with stable disease after the first line treatment with vinorelbine + xeloda. Randomized study clinical phase II |
|
|
| Ongoing | 2 | 220 | Europe | NAVELBINA, XELODA*120CPR RIV 500MG, NAVELBINA, XELODA*120CPR RIV 500MG | AZIENDA SANITARIA OSPEDALIERA \"S. GIOVANNI BATTISTA DI TORINO\" | PAZIENTI CON CARCINOMA MAMMARIO METASTATICO NON PROGREDITI DOPO UN TRATTAMENTO SISTEMICO DI PRIMA LINEA CON VINORELBINA ORALE + CAPECITABINA | | | | |
2008-002697-35: A dose-finding study of Docetaxel, Oxaliplatin and Capecitabine (TEX) as First-Line Treatment in Patients with Advanced Gastric Cancer |
|
|
| Ongoing | 2 | 24 | Europe | TAXOTERE, ELOXATIN, XELODA, TAXOTERE, ELOXATIN, XELODA | AZIENDA OSPEDALIERA DI PARMA | Patients with Advanced Gastric Cancer | | | | |
2008-002299-92: METRONOMIC CAPECITABINE IN ADVANCED HEPATOCARCINOMA:A FASE II STUDY |
|
|
| Ongoing | 2 | 50 | Europe | XELODA*120CPR RIV 500MG, XELODA*120CPR RIV 500MG | AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | Advanced Hepatocarcinoma | | | | |
2008-000657-35: A multi-centre phase II trial to assess the efficacy of epirubicin, cisplatin and capecitabine incorporating the prospective validation of molecular classifiers and exploratory metabonomics. |
|
|
| Ongoing | 2 | 57 | Europe | Cisplatin, Capecitabine, Epirubicin, 154361-50-6, | Greater Glasgow and Clyde Health Board (GGCHB)/University of Glasgow | Metastatic Carcinomas of Unknown Primary origin (CUP) | | | | |
2008-002715-40: NEOADJUVANT EPIRUBICIN-OXALIPLATIN-XELODA AND OXALIPLATIN-XELODA-RADIOTHERAPY IN LOCALLY ADVANCED, RESECTABLE, GASTRIC CANCER. A PHASE II COLLABORATIVE STUDY |
|
|
| Ongoing | 2 | 49 | Europe | FARMORUBICINA, ELOXATIN*INFUS 1FL 20ML 5MG/ML, XELODA*60CPR RIV 150MG, XELODA*120CPR RIV 500MG, FARMORUBICINA, ELOXATIN*INFUS 1FL 20ML 5MG/ML, XELODA*60CPR RIV 150MG, XELODA*120CPR RIV 500MG | CENTRO DI RIFERIMENTO ONCOLOGICO DI AVIANO | PATIENTS WITH OPERABLE GASTRIC ADENOCARCINOMA | | | | |
2007-006025-27: A phase II study of metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with bevacizumab and erlotinib (BEXE), plus trastuzumab in HER2/neu positive tumors (BEXET), in advanced breast cancer Studio di fase II di chemioterapia metronomica orale con ciclofosfamide e capecitabina combinata con bevacizumab e erlotinib (BEXE), piu\' trastuzumab nei tumori positivi per HER2/neu (BEXET)nel cancro della mammella avanzato |
|
|
| Ongoing | 2 | 66 | Europe | ENDOXAN BAXTER*50CPR RIV 50MG, XELODA*120CPR RIV 500MG, AVASTIN*INFUS 1FL 100MG 4ML, TARCEVA*30CPR RIV 150MG, HERCEPTIN*EV 1FL 150MG, ENDOXAN BAXTER*50CPR RIV 50MG, XELODA*120CPR RIV 500MG, AVASTIN*INFUS 1FL 100MG 4ML, TARCEVA*30CPR RIV 150MG, HERCEPTIN*EV 1FL 150MG | ISTITUTO EUROPEO DI ONCOLOGIA | advanced or metastatic breast cancer cancro della mammella localmente avanzato o metastatico | | | | |
2008-004996-24: A RANDOMIZED PHASE II STUDY OF TAXOTERE, OXALIPLATIN, CAPECITABINE (TOX) OR EPIDOXORUBICIN, OXALIPLATIN AND CAPECITABINE (EOX) IN PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC CANCER |
|
|
| Ongoing | 2 | 74 | Europe | Solution for infusion | AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI | PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC CANCER | | | | |
2008-003972-23: Hepatocellular carcinoma: vascular abnormalities prior to, during and following systemic anti-cancer treatment |
|
|
| Ongoing | 2 | 28 | Europe | Xeloda 500 mg and xeloda 150 mg, Xeloda, Xeloda | LUMC | The primary objective of this study is to determine the efficacy of the combination of everolimus and capecitabine in a group of patients with metastatic or locally advanced HCC. In addition, to investigate biomarkers of HCC before and during the systemic treatment reflecting states of tumour cell growth and growth arrest (state of tumour cell dormancy). | | | | |
2009-011756-22: Reinduction with liposomal anthracyclines and Capecitabine in patients with breast cancer, locally advanced (IIIA-IIIB-IIIC) HER2 negative, not obtaining a pathological complete response ( |
|
|
| Ongoing | 2 | 110 | Europe | MYOCET, XELODA, MYOCET, XELODA | AZIENDA OSPEDALIERO UNIVERSITARIA DI CAGLIARI | Population of female patients suffering from breast cancer in initial clinical stage IIIA, IIIB and IIIC not expressing HER2 and who have not obtained a pathological complete response (defined | | | | |
2009-014821-17: Intra-hepatic chemotherapy with oxaliplatin every second week in combination with systemic capecitabine and in patients with a HER2-positive tumour in combination with trastuzumab (Herceptin®) in patient with non-resectable liver metastases from breast cancer. A phase II trial in patients with limited extrahepatic disease. |
|
|
| Ongoing | 2 | 100 | Europe | capecitabine, oxaliplatin, xeloda, Eloxatin, xeloda, Eloxatin | Herlev Hospital | Breast cancer with liver metastases and limited extrahepatic metastases | | | | |
2009-014863-37: Intra-hepatic chemotherapy with oxaliplatin every second week in combination with systemic capecitabine and in patients with a HER2-positive tu,our in combination with trastuzumab (Herceptin (R)) in patientswith non-resectable liver metasatses from breast cancerA phase II trial in patients without extrahepatic disease. |
|
|
| Ongoing | 2 | 100 | Europe | capecitabine, oxaliplatin, xeloda, eloxatin, xeloda, eloxatin | Herlev hospital | Breast cancer patients with liver metastases (no extrahepatic disease) | | | | |
2009-009937-14: Metronomic Capecitabine plus Docetaxel as first line treatment for metastatic breast cancer patients: a phase II trial |
|
|
| Ongoing | 2 | 62 | Europe | TAXOTERE*INFUS FL 20MG/0,5ML+F, TAXOTERE*INFUS FL 80MG/2ML+F, XELODA*120CPR RIV 500MG, TAXOTERE*INFUS FL 20MG/0,5ML+F, TAXOTERE*INFUS FL 80MG/2ML+F, XELODA*120CPR RIV 500MG | ISTITUTO EUROPEO DI ONCOLOGIA | Metastatic breast cancer | | | | |
2009-017776-24: A pilot study evaluating response to induction chemotherapy with oxaliplatin, capecitabine and bevacizumab in patients with extensive peritoneal carcinomatosis of colorectal origin. |
|
|
| Ongoing | 2 | 35 | Europe | Xeloda, Avastin, Xeloda, Avastin | | Induction chemotherapy for Peritoneal Carcinomatosis of Colorectal Cancer | | | | |
2010-018363-42: A phase II dose finding study of induction cisplatin, docetaxel and escalating doses of capecitabine followed by concurrent cetuximab and radiotherapy in locally advanced inoperable head and neck squamous cell carcinoma |
|
|
| Ongoing | 2 | 30 | Europe | ERBITUX*INFUS 1FL 100ML 5MG/ML, XELODA*120CPR RIV 500MG, XELODA*60CPR RIV 150MG, CISPLATINO TEVA*EV 50MG 100ML, TAXOTERE*INFUS FL 80MG/2ML+F, ERBITUX*INFUS 1FL 100ML 5MG/ML, XELODA*120CPR RIV 500MG, XELODA*60CPR RIV 150MG, CISPLATINO TEVA*EV 50MG 100ML, TAXOTERE*INFUS FL 80MG/2ML+F | ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE \"G. PASCALE\" | locally advanced inoperable head and neck squamous cell carcinoma | | | | |
2010-019233-97: CHEMORADIOTHERAPY FOR RECTAL CANCER IN THE DISTAL RECTUMFOLLOWED BY ORGAN-SPARING TRANSANAL ENDOSCOPICMICROSURGERY |
|
|
| Ongoing | 2 | 55 | Europe | Capecitabine, Xeloda, Xeloda | University Medical Centre Nijmegen | T1-3 N0 M0 distal rectal tumor (below 10 cm), based on diagnostic imaging | | | | |
2010-019463-10: MULTICENTER PHASE II STUDY FOR THE EVALUATION OF BEVACIZUMAB, OXALIPLATIN AND CAPECITABINE IN THE TREATMENT OF ELDERLY PATIENTS WITH ADVANCED COLORECTAL CANCER STUDIO MULTICENTRICO DI FASE II PER LA VALUTAZIONE DELL\'ASSOCIAZIONE DI BEVACIZUMAB (AVASTIN), OXALIPLATINO E CAPECITABINA (XELODA) NEL TRATTAMENTO DEI PAZIENTI ANZIANI (ELDERLY) AFFETTI DA CANCRO DEL COLON-RETTO AVANZATO (BOXE TRIAL) |
|
|
| Ongoing | 2 | 44 | Europe | XELODA, OXALIPLATINO RAT, AVASTIN, XELODA, OXALIPLATINO RAT, AVASTIN | AZIENDA OSPEDALIERA S. CARLO | advanced colorectal cancer cancro del colon-retto avanzato. | | | | |
2010-019602-16: A study of lapatinib in combination with oxaliplatin and capecitabine in early HER-2 overexpressing oesophageal and gastric cancers |
|
|
| Ongoing | 2 | 25 | Europe | Oxaliplatin, Capecitabine(Xeloda) 150 mg tablets, Capecitabine (Xeloda) 500mg tablets, Lapatinib (Tyverb), Eloxatin, Xeloda 150mg tablets, Xeloda, Tyverb, Eloxatin, Xeloda 150mg tablets, Xeloda, Tyverb | Cambridge University Hospitals NHS Foundation Trust | Oesophagogastric adenocarcinoma | | | | |
2011-000273-31: Intra-hepatic and systemic chemotherapy with or without antibody for patients with non-resectable liver metastasis from solid tumours |
|
|
| Ongoing | 2 | 100 | Europe | capacetabine, Oxaliplatin, Gemcitabin, Cetuximab, mitomycin, PR2, Xeloda, Oxaliplatin, Gemcitabin, Erbitux, mitomycin, Xeloda, Oxaliplatin, Gemcitabin, Erbitux, mitomycin | Herlev University Hospital | Intra-hepatic and systemic chemotherapy with or without antibody for patients with non-resectable liver metastasis from solid tumours | | | | |
2010-022091-31: Bevacizumab + Folfox4 or Xelox2 as first- line treatment in colorectal cancer. Randomized phase II study. |
|
|
| Ongoing | 2 | 132 | Europe | AVASTIN*INFUS 1FL 400MG 16ML, FLUOROURACILE TEVA*IV 5G 100ML, ELOXATIN*INFUS 1FL 40ML 5MG/ML, XELODA*120CPR RIV 500MG, LEDERFOLIN*INFUS 1FL 100MG, AVASTIN*INFUS 1FL 400MG 16ML, FLUOROURACILE TEVA*IV 5G 100ML, ELOXATIN*INFUS 1FL 40ML 5MG/ML, XELODA*120CPR RIV 500MG, LEDERFOLIN*INFUS 1FL 100MG | GOIM GRUPPO ONCOLOGICO MERIDIONALE | Oncologic patients | | | | |
2010-023794-19: II Phase Study for the evaluation of Full-oral, metronomic schedule of Vinorelbine (VNB) and Capecitabine (CAPE) Studio di Fase II di valutazione della schedula metronomica orale Vinorelbina+Capecitabina |
|
|
| Ongoing | 2 | 120 | Europe | XELODA, NAVELBINE, XELODA, NAVELBINE | AZIENDA OSPEDALIERA S. GERARDO DI MONZA, A.O. San Gerardo di Monza | Breast cancer Tumore mammario | | | | |
|
2010-024266-21: A phase II study evaluating the role of the combination of Vinorelbine,cyclophosphamide and capecitabine administered metronomically, that means low doses daily orally, in patients with advanced breast cancer Studio di fase II che valuta il ruolo della combinazione di tre farmaci chemioterapici Vinorelbina, Ciclofosfamide e Capecitabina, somministrati in modalita\' metronomica, ossia a basse dosi date quotidianamente per bocca, alle pazienti affette da carcinoma della mammella metastatico |
|
|
| Ongoing | 2 | 100 | Europe | ENDOXAN BAXTER*50CPR RIV 50MG, NAVELBINE*1CPS 30MG, NAVELBINE*1CPS 20MG, XELODA*120CPR RIV 500MG, ENDOXAN BAXTER*50CPR RIV 50MG, NAVELBINE*1CPS 30MG, NAVELBINE*1CPS 20MG, XELODA*120CPR RIV 500MG | ISTITUTO EUROPEO DI ONCOLOGIA, Istituto Europeo Oncologia, PIERRE FABRE | Metastatic breast cancer Tumore della mammella metastatico | | | | |
2011-005495-42: Individualised choise of 1.line chemotherapy of metastatic colo-rectal cancer. Can the blood test: TIMP-1 help the doctor to choose the best chemotherapy for the individual patient? Individualiseret valg af første linie kemoterapi af tarmkræft med spredning.Støtter blodprøven: TIMP-1 (cancer markør) lægen at foretage bedste valg af 1.linie kemoterapi? |
|
|
| Ongoing | 2 | 210 | Europe | Xeloda, Avastin, oxaliplatin, irinotecan, WC500058151, WC500029271, Xeloda, Avastin, oxaliplatin, irinotecan, Xeloda, Avastin, oxaliplatin, irinotecan | Kell Osterlind, Rigshospitalet | Metastatic colon or rectal cancer Metastatisk tarmkræft der udgår fra tyk- eller endetarm | | | | |
2012-000751-13: Phase II study of first-line WHIT panitumumab and capecitabine in elderly patients with metastatic colorectal cancer and wild type KRAS Estudio de fase II de panitumumab y capecitabina como tratamiento de primera línea en pacientes ancianos con cáncer colorrectal metastásico KRAS no mutado |
|
|
| Ongoing | 2 | 36 | Europe | PANITUMUMAB, CAPECITABINA, PANITUMUMAB, CAPECITABINA, VECTIBIX 20mg/ml concentrado para solución para infusión, VECTIBIX 20mg/ml concentrado para solución para infusión | Grupo Gallego de Investigación en Tumores Digestivos - GITuD, AMGEN S.A. | First-line treatment for elderly patients with metastatic colorectal cancer (mCRC) and wild type KRAS Tratamiento de primera línea para pacientes ancianos con cáncer colorrectal metastásico (CCRm) KRAS no mutado. | | | | |
2012-001850-24: Comparison of chemotherapy with radiochemotherapy as treatment of patients with pancreatic carcinoma, which cannot be removed by surgery |
|
|
| Ongoing | 2 | 68 | Europe | Irinotecan 20 mg, Fluorouracil Accord 50 mg/ml, Oxaliplatin 5 mg/ml, xeloda, Calciumfolinat “Ebewe”, Irinotecan 20 mg, Fluorouracil Accord 50 mg/ml, Oxaliplatin 5 mg/ml, xeloda, Calciumfolinat “Ebewe” | ABCSG (Austrian Breast & Colorectal Cancer Study Group), ABCSG | locally advanced pancreatic carcinoma | | | | |
2012-005329-56: .A phase ll trial of combination chemotherapy with intravenous oxaliplatin combined with tablet capecitabin in patients with recidivant breastcancer En fase II undersøgelse af kombinationsbehandling med intravenøs oxaliplatin og tablet capecitabin til patienter med recidiv af brystkræft. |
|
|
| Ongoing | 2 | 50 | Europe | Oxaliplatin, Capecitabine, | Dept of oncology, Dept of oncology, Herlev Hospital | breastcancer with metastases Behandling af avanceret brystkræft | | | | |
2013-001714-15: Phase II trial of capecitabine (Xeloda®) + nab-paclitaxel (Abraxane®) in patients with metastatic pancreatic cancer |
|
|
| Ongoing | 2 | 32 | Europe | Abraxane, Abraxane | Med. Univ. Wien, Klinik f. Innere Med. I, Onkologie | metastatic pancreatic adenocarcinoma | | | | |
2013-003932-56: ESPAC-5F: European Study Group for Pancreatic Cancer - Trial 5F |
|
|
| Ongoing | 2 | 100 | Europe | Gemcitabine, Capecitabine, Irinotecan, 5-Fluorouracil, Folinic acid, oxaliplatin, SUB02324MIG, SUB12474MIG, SUB02772MIG, SUB27520, SUB63776, SUB09490MIG, | University of Liverpool, Royal Liverpool and Broardgreen University Hospitals Trust, Cancer Research UK | Borderline resectable pancreatic cancer. | | | | |
2014-000256-28: A study to assess the use of Octreotide in the prevention or reduction of diarrhoea associated with lapatinib and capecitabine treatment in patients with metastatic breast cancer. |
|
|
| Ongoing | 2 | 40 | Europe | Sandostatin® LAR®, Sandostatin, N/A, Sandostatin® LAR® (10 mg, 20 mg or 30 mg powder and solvent for suspension for injection), Sandostatin (0.05mg/ml, 0.1 mg/ml, 0.5 mg/ml Ampoules and Multidose Vial 1 mg/5 ml), Tyverb, Sandostatin® LAR® (10 mg, 20 mg or 30 mg powder and solvent for suspension for injection), Sandostatin (0.05mg/ml, 0.1 mg/ml, 0.5 mg/ml Ampoules and Multidose Vial 1 mg/5 ml), Tyverb | GlaxoSmithKline research & Development, GlaxoSmithKline R&D | Diarrhoea associated with treatment with lapatinib and capecitabine for metastatic breast cancer | | | | |
ChiCTR-ONC-13004082: Phase II study of preoperative Intensity-Modulated Radiotherapy（IMRT）and capecitabine in locally advanced cectal cancer |
|
|
| Completed | 2 | 6 | | Preoperative IMRT (pGTV 55Gy/25 fractions, PTV 45 Gy/5, Chemotherapy: oral capecitabine 825g/m2 per day, twice a day from day 1 to day 14; after 6 to 8 weeks of radiotherapy, conduct TME surgery | Jinhua Municipal Central Hospital; Jinhua Municipal Central Hospital, Jinhua Municipal Science and Technology Bureau and Jinhua Municipal Central Hospital | Rectal cancer | | | | |
ChiCTR-TRC-13004205: Phase II Clinical Study of UTD1 in Combination with Capecitabine or UTD1 Alone in Patients with Metastatic and Locally Advanced Breast Cancer |
|
|
| Completed | 2 | 90 | | 30mg/m2/day UTD1 (administered for consecutive 5 days)+2000mg Capecitabine (administered for consecutive 14 days). Dosing is repeated every 21 days. ;40mg/m2/day UTD1(administered for consecutive 5 days). Dosing is repeated every 21 days. | Cancer Hospital, Chinese Academy of Medical Sciences; Level of the institution：, Beijing Biostar Technologies, Ltd. | Metastatic or Locally Advanced Breast Cancer | | | | |
2008-000528-22: Phase I/II study of Lapatinib in combination with Capecitabine and Vinorelbine for the second-line treatment of patients with refractory locally recurrent or metastatic breast cancer with ErbB2 overexpression Studio di fase I-II con Lapatinib in combinazione con capecitabina e vinorelbina come seconda linea di trattamento in pazienti con carcinoma mammario con iperespressione di ErbB2 localmente avanzato o metastatico in progressione ad una prima linea di chemioterapia associata a trastuzumab |
|
|
| Ongoing | 2 | 80 | Europe | XELODA, NAVELBINE 10, XELODA, NAVELBINE 10 | GRUPPO ONCOLOGICO ITALIANO DI RICERCA | Patients with HER2 positive metastatic or locally recurrent adenocarcinoma of the breast Pazienti con carcinoma mammario metastatico o con recidiva locale HER2 positivo | | | | |
2013-001630-18: Multicentre phase 2 study of neoadjuvant oxaliplatin and capecitabine followed by chemo-radiotherapy in patients with locally advanced carcinoma of esphago-gastric junction. Studio multicentrico di fase II, di chemioterapia di induzione con Oxaliplatino e Capecitabina seguito da chemio-radioterapia con intento neoadiuvante in pazienti affetti da carcinoma della giunzione esofago-gastrica localmente avanzato. |
|
|
| Ongoing | 2 | 40 | Europe | oxaliplatin, capecitabine, Xeloda, Xeloda | Istituto Nazionale per lo Studio e la Cura dei Tumori di Napoli – Fondazione “G.Pascale”, none | Locally advanced carcinoma (squamous or adenocarcinoma) of the esophago-gastric junction Siewert type I and II Carcinoma (adenocarcinoma o carcinoma squamoso) della giunzione esofago-gastrica tipo I e II secondo Siewert localmente avanzato | | | | |
2014-003067-38: 177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) plus Capecitabine versus Lu-PRRT in FDG positive, gastro-entero-pancreatic neuroendocrine tumors: a randomized phase II study. (Lu-Ca-S) Terapia radiorecettoriale con 177Lu-dotatate (Lu-PRRT) più capecitabina verso Lu-PRRT in pazienti FDG positivi con neoplasia neuroendocrina gastro-entero-pancreatica: studio randomizzato di fase II. (Lu-Ca-S) |
|
|
| Not yet recruiting | 2 | 176 | Europe | CAPECITABINE_IRSTIRCCS, LU-DOTATATE_IRSTIRCCS, CAPECITABINE_IRSTIRCCS, LU-DOTATATE_IRSTIRCCS, Tablet, Solution for infusion, CAPECITABINA ACCORD - 500 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PVC/PVDC/ALU) - 60X1 COMPRESSE (DOSE UNITARIA) | ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS, IRST IRCCS | gastro-entero-pancreatic neuroendocrine tumors (GEP-NET) NET (tumori neuroendocrini) del tratto gastro-entero-pancreatico (GEP), gastro-entero-pancreatic neuroendocrine tumors (GEP-NET) NET (tumori neuroendocrini) del tratto gastro-entero-pancreatico (GEP), Diseases [C] - Cancer [C04] | | | | |
2005-002808-42: Estudio abierto, no controlado, multicéntrico, de fase II para estudiar la eficacia y seguridad de una combinación de Capecitabina + Bevacizumab, en 1ª línea de tratamiento, en pacientes ancianos no susceptibles de poliquimioterapia con adenocarcinoma colorrectal avanzado o metastático |
|
|
| Ongoing | 2 | 60 | Europe | Bevacizumab, capecitabina, Avastin 25 mg/ml concentrado para solución para perfusión, Xeloda 150 mg comprimido con cubierta pelicular, Avastin 25 mg/ml concentrado para solución para perfusión, Xeloda 150 mg comprimido con cubierta pelicular | GRUPO ONCOPAZ | Adenocarcinoma colorrectal localmente avanzado o metastático, no resecable. | | | | |
2006-005499-42: Tratamiento de inducción con XELOX-Bevacizumab en el adenocarcinoma localmente avanzado de recto: Estudio fase II |
|
|
| Ongoing | 2 | 44 | Europe | AVASTIN 25 mg/ml concentrado para solución para perfusión, AVASTIN 25 mg/ml concentrado para solución para perfusión | ACROSS (Associació Catalana de Recerca Oncològica i les seves implicacions Sanitàries i Socials) | Adenocarcinoma localmente avanzado de recto. | | | | |
2009-016708-21: Essai multicentrique de phase II évaluant l\'efficcacité et la tolérance de l\'association de bevacizumab, paclitaxel et capecitabine en première ligne chez des patientes atteintes de cancer du sein métastatique ou localement avancé récepteurs triples negatifs . |
|
|
| Ongoing | 2 | 62 | Europe | Bevacizumab, Paclitaxel, capecitabine Xeloda, R04876646, Code CIP : 3657456, Code CIP : 3657462, Avastin, paclitaxel, XELODA 150 mg, XELODA 500 mg, Avastin, paclitaxel, XELODA 150 mg, XELODA 500 mg | ARCAGY | Cancer du sein métastatique | | | | |
2011-002191-16: A Phase II study to assess efficacy and safety of a combination chemotheraphy in first-line treatment with Xeloda + Oxaliplatin + Avastin or Xeloda + Irinotecan + Avastin. At progression of disease (second-line treatment) patient will receive Xeloda + Oxaliplatin + Avastin when received Xeloda + Irinotecan + Avastin in first-line or: At progression of disease (second-line treatment) patient will receive Xeloda + Irinotecan + Avastin if recieved Xeloda + Oxaliplatin + Avastin in first-line. |
|
|
| Ongoing | 2 | 120 | Europe | Xeloda, Avastin, Irinotecan, Oxaliplatin, RO0091978, RO04876646, Xeloda, Avastin, IMP with the active substance irinotecan and a marketing authorization in Austria will be used., IMP with the active substance oxaliplatin and a marketing authorization in Austria will be used., Xeloda, Avastin, IMP with the active substance irinotecan and a marketing authorization in Austria will be used., IMP with the active substance oxaliplatin and a marketing authorization in Austria will be used. | Medizinische Universität Wien, Univ.Klink f. Innere Medizin I, Roche Austria GmbH | Histologically or cytologically confirmed carcinoma of the colon and/or rectum with evidence of metastases. Diagnosis of metastatic disease according to RECIST not more than 3 months prior to enrolment No prior chemotherapeutic treatment for metastatic colorectal carcinoma | | | | |
| Active, not recruiting | 2 | 48 | US | FOLFIRINOX, 5-FU, Oxaliplatin, Irinotecan, Capecitabine, Short Course Radiation, Surgery | Massachusetts General Hospital, National Cancer Institute (NCI) | Pancreatic Cancer | 03/17 | 01/22 | | |
ChiCTR-ONC-14004365: Nab-paclitaxel and capecitabine as first-line chemotherapy in Chinese patients with HER2-negative metastatic breast cancer |
|
|
| Recruiting | 2 | 30 | | Xeloda | Peking University Cancer Hospital (Beijing Cancer Hospital); Peking University Cancer Hospital (Beijing Cancer Hospital), none | Breast Cancer | | | | |
2017-003621-15: A Phase II study of a Combination of Eribulin and capecitabiNe in second line Treatment after the failure of gemcitabine/abraxane first line in advanced pancreatic cancer Studio di Fase II di eribulina in combinazione con capecitabina per il trattamento di seconda linea in pazienti affetti da carcinoma pancreatico avanzato dopo fallimento di terapia di prima linea con gemcitabina/abraxane. |
|
|
| Not yet recruiting | 2 | 25 | Europe | HALAVEN, Capecitabina accord 150, Capecitabina Accord 500, [-], Solution for infusion, Film-coated tablet, HALAVEN - 0.44MG/ML - SOLUZIONE INIETTABILE - USO ENDOVENOSO - FLACONCINO(VETRO) 2ML 6 FLACONCINI, CAPECITABINA ACCORD - 150 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PVC/PVDC/ALU) - 120 COMPRESSE, CAPECITABINA ACCORD - 500 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PVC/PVDC/ALU) - 120 COMPRESSE | AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA, EISAI srl | advanced pancreatic cancer tumore del pancreas avanzato, advanced pancreatic cancer tumore del pancreas avanzato, Diseases [C] - Cancer [C04] | | | | |
2017-004652-35: Second line ERIbulin followed by CApecitabine or the reverse sequence in HER2-negative Metastatic Breast Cancer (MBC) patients: a randomized phase II study – ERICA trial ERIbulina in seconda linea seguita da CApecitabina o sequenza inversa in pazienti con carcinoma mammario metastatico (MBC) HER2-negativo: uno studio randomizzato di fase II – Studio ERICA |
|
|
| Ongoing | 2 | 150 | Europe | HALAVEN, Xeloda, [Eribulina], [Capecitabina], Solution for injection, Film-coated tablet, HALAVEN - 0.44MG/ML - SOLUZIONE INIETTABILE - USO ENDOVENOSO - FLACONCINO(VETRO) 2ML 6 FLACONCINI, XELODA - 500 MG 120 COMPRESSE FILMRIVESTITE IN BLISTER USO ORALE | CONSORZIO ONCOTECH, EISAI S.r.l. | HER2-negative Metastatic Breast Cancer Carcinoma mammario metastatico HER2-negativo, Metastatic Breast Tumour Tumore al seno metastatico, Diseases [C] - Cancer [C04] | | | | |
2018-000655-40: Adjuvant capecitabine in patients with early diagnosis of pseudomyxoma peritonei (PMP), who underwent cytoreductive surgery (CRS) and intraperitoneal hyperthermic chemotherapy (HIPEC). Capecitabina adiuvante nei pazienti con prima diagnosi di pseudomyxoma peritonei (PMP), sottoposti a chirurgia citoriduttiva (CRS) e chemioterapia ipertermica intraperitoneale (HIPEC). |
|
|
| Not yet recruiting | 2 | 28 | Europe | Capecitabina, Film-coated tablet, CAPECITABINA ACCORD - 500 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PVC/PVDC/ALU) - 120X1 COMPRESSE (DOSE UNITARIA) | FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI", AIRC | PMP PSEUDOMYXOMA PERITONEI PMP PSEUDOMYXOMA PERITONEI, PMP PSEUDOMYXOMA PERITONEI, characterized by mucinous tumors in the abdomen and in the pelvis PMP Pseudomyxoma del peritoneo,caratterizzato da tumori mucinosi nell'Addome e nel Bacino, Diseases [C] - Cancer [C04] | | | | |
2015-003572-79: NEOADJUVANT THERAPY ACCORDING TO DOCETAXEL, OXALIPLATINO AND CAPECITABINA DIAGNOSIS IN ADENOCARCINOMA SIEWERT III TERAPIA NEOADIUVANTE SECONDO SCHEMA DOCETAXEL, OXALIPLATINO E CAPECITABINA NELL'ADENOCARCINOMA SIEWERT III |
|
|
| Ongoing | 2 | 86 | Europe | TAXOTERE, XELODA, Oxaliplatino Accord, Oxaliplatino, Concentrate for solution for infusion, Film-coated tablet, TAXOTERE - 20 MG CONCENTRATO PER INFUSIONI IV + SOLVENTE, XELODA - 500 MG 120 COMPRESSE FILMRIVESTITE IN BLISTER USO ORALE, OXALIPLATINO ACCORD HEALTHCARE - 5MG/ML POLVERE PER SOLUZIONE PER INFUSIONE 1 FLACONCINO DI VETRO DA 100 MG | AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA, AOUI Verona | Adenocarcinoma of cardias siewert III adenocarcinoma del cardias siewert III, Adenocarcinoma Adenocarcinoma, Diseases [C] - Cancer [C04] | | | | |
2016-004156-29: A trial looking at two chemotherapy treatments given prior to surgery for pancreatic cancer, looking at biomarker development |
|
|
| Not yet recruiting | 2 | 242 | Europe | Abraxane, Gemcitabine, Oxaliplatin, Fluorouracil, Folinic acid, Capecitabine, Powder for solution for infusion, Concentrate for solution for infusion, Solution for injection/infusion, Film-coated tablet, Abraxane | NHS Greater Glasgow and Clyde | Pancreatic cancer, Pancreatic cancer, Diseases [C] - Cancer [C04] | | | | |
ChiCTR-OIC-17012236: Capecitabine combined zoledronic acid (CZ) versus capecitabine monotherapy (CAP) for first-line treatment of advanced three negative breast cancer without bone metastasis: a phase II clinical study |
|
|
| Not yet recruiting | 2 | 254 | | Capecitabine combined with zoledronic acid (CZ) ;capecitabine | Cancer Hospital Affiliated to Harbin Medical University; Cancer Hospital Affiliated to Harbin Medical University, Undertake by oneself | mammary cancer | | | | |
ELTOP, UMIN000005219: Japanese A Randomized Phase II Study Comparing Trastuzumab + Capecitabine Combination (HX Therapy) Versus Lapatinib + Capecitabine Combination (LX Therapy) in HER2-Positive Metastatic or Unresectable Locally Advanced Breast Cancer Previously Treated with |
|
|
| Completed | 2 | 110 | Japan | Herceptin (trastuzumab) - Roche, capecitabine - Generic mfg., lapatinib - Generic mfg. | GlaxoSmithKline K.K. | HER2-positive metastatic or unresectable locally advanced breast cancer | | | | |
NEOLAR, NCT03280407: NEOadjuvant Chemotherapy Only Compared With Standard Treatment for Locally Advanced Rectal Cancer |
|
|
| Recruiting | 2 | 124 | Europe | Capecitabine, FOLFOX regimen (oxaliplatin/leucovorin/5FU), FOLFOX (oxaliplatin/leucovorin/5FU), CAPOX (oxaliplatin/capecitabine) | Zealand University Hospital | Colorectal Neoplasm, Colorectal Cancer, Rectal Neoplasms, Chemotherapy Effect, Intestinal Disease, Intestinal Neoplasms, Rectal Cancer | 12/18 | 12/24 | | |
| Completed | 2 | 16 | Europe | Hyperfractionated external beam radiation | Aarhus University Hospital, Oslo University Hospital | Rectal Cancer, Recurrence, Radiation Toxicity | 01/19 | 01/23 | | |
